Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HEPLISAV-B in Subjects 11-55 Years Old
NCT00511095Phase 2Completed
- Sponsor
- Dynavax Technologies
- Start
- Jun 2007
- Primary completion
- Oct 2007
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Heplisav-B in hepatitis B (HBV), sponsored by Dynavax Technologies. Primary endpoint: Percentage of Participants With Local and Systemic Post-injection Reaction Rates. Started Jun 2007; status: completed.
02
Drugs
Heplisav-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00511095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511095.